Glass House Brands (GLAS) Land & Improvements (2021 - 2024)
Glass House Brands' (GLAS) quarterly Land & Improvements came in at $70.9 million in Q1 2024, little changed on a QoQ basis from $70.9 million in Q4 2023.
Glass House Brands (GLAS) Land & Improvements (2021 - 2024) Analysis & Trends
Glass House Brands (GLAS) has 4 years of Land & Improvements data on file, last reported at $70.9 million in Q1 2024.
- On a quarterly basis, Land & Improvements changed N/A year-over-year to $70.9 million in Q1 2024; TTM through Mar 2024 was $70.9 million, a N/A change from a year earlier, with the FY2023 full-year figure at $70.9 million, changed N/A from the prior year.
- Land & Improvements for Q1 2024 stood at $70.9 million, roughly flat from $70.9 million in the prior quarter.
- Over the last five years, Land & Improvements for GLAS reached as high as $70.9 million in Q4 2023 and fell as low as $70.8 million in Q4 2021.
- Historically, Land & Improvements has averaged $70.8 million across 4 years, with a median of $70.8 million in 2021.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Land & Improvements (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | - |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | - |
| 10 | Glass House Brands | 873.84 Mn | 845.91 Mn | 10.02 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 70.89 Mn |
| Dec 31, 2023 | 70.89 Mn |
| Mar 31, 2022 | 70.78 Mn |
| Dec 31, 2021 | 70.78 Mn |